Talks & Publications:
- Ghosh DD, Chowdhury R R, Dutta R, Mukhopadhyay I, Mukhopadhyay A, Roychoudhury S. In-siIico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping withTP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries. https://doi.org/10.1016/j.gore.2023.101209
- Mandal P, Bhattacharjee B, Sen S, Bhattacharya A, Saha SS, Chowdhury RR, Mondal NR, Chakrabarty B, Chatterjee T, Roy S, Sengupta S. Predominance genomically defined A lineage of HPV16 over D lineage in Indian patients from Eastern India with squamous cell carcinoma of the cervix in association with distinct oncogenic Transl Oncol. 2021 Oct 27;15(1):101256.doi: 10.1016/j.tranon.2021.101256. Epub ahead of print. PMID: 34717279; PMCID: PMC8564679.
- Kurtz JE,Gebski V, SukhinV, Carey M, Kong I, Glasspool RM, BerekJS, de Paiva Batista M, Hall M, KimJW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY,
Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA. Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M; Gynecologic Cancer Inter Group (GCIG) symptom benefit committee.
Incorporating patient centered benefits as endpointsin randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecol Oncol. 2021 May; 161(2):502-507. doi: 10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19. PMID: 33612336.
Poster presentation
- Mukhopadhyay A, Ghosh T, Bhattacharjee D, Chakraborty D, Gupta , Roychowdhury I, Chatterjee P, Vemekar M, Chowdhury RR, Intermittent PARP Inhibitor Regimen In Ovarian Cancer (IPIROC):Origin and Feasibility Of Implementing A Proof-Of -Concept Exploratory Study. 18 October 2023 IGCS Abstracts.
